Get the Stockscreener App
19.60
2.40%
0.46
Nurix Therapeutics Inc stock is traded at $19.60, with a volume of 573.65K.
It is up +2.40% in the last 24 hours and down -1.16% over the past month.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
See More
Previous Close:
$19.14
Open:
$19.42
24h Volume:
573.65K
Relative Volume:
0.66
Market Cap:
$1.39B
Revenue:
$80.89M
Net Income/Loss:
$-144.73M
P/E Ratio:
-7.3684
EPS:
-2.66
Net Cash Flow:
$-83.87M
1W Performance:
+5.38%
1M Performance:
-1.16%
6M Performance:
-5.68%
1Y Performance:
+140.20%
1-Day Range:
$19.32
$20.15
1-Week Range:
$18.75
$20.50
52-Week Range:
$7.65
$29.56
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Name
Nurix Therapeutics Inc
Sector
Industry
Phone
(415) 660-5320
Address
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
Compare NRIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
19.60 | 1.39B | 80.89M | -144.73M | -83.87M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-11-24 | Initiated | Jefferies | Buy |
| Sep-06-24 | Resumed | Robert W. Baird | Outperform |
| Jul-31-24 | Initiated | Truist | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-09-23 | Initiated | Barclays | Overweight |
| Feb-28-23 | Initiated | Oppenheimer | Outperform |
| Oct-11-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-31-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Dec-29-21 | Initiated | H.C. Wainwright | Buy |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-30-21 | Resumed | Piper Sandler | Overweight |
| Apr-30-21 | Initiated | RBC Capital Mkts | Outperform |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Nov-19-20 | Initiated | Robert W. Baird | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
| Aug-18-20 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-18-20 | Initiated | Stifel | Buy |
View All
Nurix Therapeutics Inc Stock (NRIX) Latest News
Nurix Therapeutics (NASDAQ:NRIX) Given "Overweight" Rating at Stephens - MarketBeat
We Think Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Drive Business Growth - Yahoo Finance
Learn to Evaluate (NRIX) using the Charts - Stock Traders Daily
Nurix Therapeutics Unveils 2025 Objectives and Achievements - TipRanks
Nurix Therapeutics Outlines 2025 Goals and Objectives for Advancement of Its Robust Pipeline in Cancer and Autoimmune Diseases - The Manila Times
Nurix's NX-5948 Cancer Drug Achieves 75% Response Rate, Secures Fast Track Status - StockTitan
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Shares Down 7.1%Time to Sell? - MarketBeat
Nurix Therapeutics: Speculative Bet On BTK Degraders And Targeted Protein Modulation (NASDAQ:NRIX) - Seeking Alpha
Strength Seen in SpringWorks Therapeutics (SWTX): Can Its 6.0% Jump Turn into More Strength? - MSN
Nurix Therapeutics (NASDAQ:NRIX) Trading Up 3.9%What's Next? - MarketBeat
Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Nurix Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
(NRIX) Trading Report - Stock Traders Daily
Nurix Therapeutics: Still A Cool Story, But This Price Point Remains Too Hot For Me - Seeking Alpha
Nurix therapeutics chief legal officer sells $112k in stock By Investing.com - Investing.com Nigeria
Nurix therapeutics chief legal officer sells $112k in stock - Investing.com India
How the (NRIX) price action is used to our Advantage - Stock Traders Daily
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Bought by Geode Capital Management LLC - Defense World
Franklin Resources Inc. Has $2.77 Million Stock Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Geode Capital Management LLC Has $32.54 Million Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Barclays PLC Increases Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Barclays PLC Buys 56,190 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World
Nurix Therapeutics (NASDAQ:NRIX) Stock Price Down 3.2%Here's Why - MarketBeat
Jane Street Group LLC Has $3.54 Million Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
State Street Corp Sells 337,262 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia - The Manila Times
Nurix Therapeutics Receives U.S. FDA Fast Track Designation - GlobeNewswire
Nurix's BTK Degrader NX-5948 Earns FDA Fast Track Status for Rare Blood Cancer Treatment - StockTitan
State Street Corp Cuts Stock Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
NX-5948 Earns Fast Track Designation in R/R Waldenström Macroglobulinemia - Cancer Network
Nurix Therapeutics' SWOT analysis: btk degrader stock shows promise amid challenges - Investing.com
Lord Abbett & CO. LLC Purchases Shares of 350,640 Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Brokerages Set Nurix Therapeutics, Inc. (NASDAQ:NRIX) Target Price at $30.35 - MarketBeat
When (NRIX) Moves Investors should Listen - Stock Traders Daily
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stake Boosted by The Manufacturers Life Insurance Company - Defense World
BTIG Initiates Coverage of Nurix Therapeutics (NRIX) with Buy Recommendation - MSN
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Acquired by Fmr LLC - MarketBeat
Is Nurix Therapeutics (NRIX) the Worst ARK Stock to Buy According to Short Sellers? - MSN
Nurix Therapeutics (NASDAQ:NRIX) Given New $35.00 Price Target at HC Wainwright - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Purchased by Wellington Management Group LLP - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Coverage Initiated at BTIG Research - MarketBeat
Nurix Therapeutics' (NRIX) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
Nurix Therapeutics Reports Promising Trial Results for NX-5948 - TipRanks
Nurix Therapeutics's SWOT analysis: btk degrader stock shows promise amid challenges By Investing.com - Investing.com South Africa
Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting - The Manila Times
Nurix Therapeutics's SWOT analysis: btk degrader stock shows promise amid challenges - Investing.com India
Nurix Therapeutics Presents New Positive Data from Phase - GlobeNewswire
Charles Schwab Investment Management Inc. Sells 111,684 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Shares Up 8.3%Here's What Happened - MarketBeat
Nurix Therapeutics Inc Stock (NRIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):